Status:
COMPLETED
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Lead Sponsor:
Bayer
Conditions:
Relapsing-Remitting Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digita...
Eligibility Criteria
Inclusion
- Outpatients with the diagnosis of Multiple Sclerosis and decision by the investigator to prescribe Betaferon.The decision for treatment type and duration is taken before offering the patient the possibility to participate in the study.
Exclusion
- Patients, who do not meet the Clinically Isolated Syndrome (CIS) or Relapsing/Remitting Multiple Sclerosis (RRMS) criteria, should not be included.
- Exclusion criteria must be read in conjunction with the German product information.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
702 Patients enrolled
Trial Details
Trial ID
NCT00902135
Start Date
May 1 2009
End Date
August 1 2014
Last Update
July 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Germany